Figure 3.
Ezetimibe reduced a circulating oxidative marker, derivatives of reactive oxidative metabolites (d-ROMs), in patients with atherosclerosis-prone with hypercholesterolemia. Measurements of d-ROMs were assessed before and after 22-week ezetimibe administration in patients with atherosclerosis-prone hypercholesterolemia (n = 14). Bars represent the mean value of the ratio ± SD.